Adis Journals Make Impressive Impact Factor Gains

BRIDGEWATER, N.J., Aug. 10 /PRNewswire/ -- Wolters Kluwer Pharma Solutions, Inc., a leading provider of scientific information and analytics to pharmaceutical and healthcare professionals, today announced strong impact factor (IF) gains for its line of drug therapy and patient management journals.  Ten of the 12 Adis journals that carried IFs in 2008 bettered their performance in 2009 according to the annual Journal Citation Reports® published in June.

The most impressive gains over 2008 were made by BioDrugs (IF 3.506) – up more than 55 percent, and Drugs in R&D (IF 1.354), which was up more than 35 percent.  Drugs in R&D is the first open-access journal published by Adis.  Other standout performers include Adis' premiere pharmacology journal, Drugs (IF 4.732), up 14 percent, and the American Journal of Clinical Dermatology (IF 1.820) – up 17 percent.  

The American Journal of Cardiovascular Drugs, a newly tracked journal in 2009, received its first impact factor (1.964) and was ranked #47 in the Cardiac & Cardiovascular System category.

"In a year when the publishing industry was struggling to overcome a global recession, we're pleased to say that Adis journals continued to make strides with medical and scientific researchers who rely on these trusted resources on a daily basis," said Iain Spray, Adis Product Manager, Wolters Kluwer Pharma Solutions.  "These IF gains are unquestionably the result of the hard work and professionalism of our global team of editors, authors and researchers who collectively ensure that Adis continues to stand for quality."

An impact factor quantifies the relative influence of a scientific or scholarly journal in the marketplace.  It is a measure of the frequency with which the average article in a journal has been cited in a given year.

For more than 40 years, medical and scientific researchers have turned to Adis for its high quality, peer-reviewed content.  Adis journals, covering the evidence-based pharmacology spectrum from clinical pharmacology to drug development and drug safety, to pharmacoeconomics, medical biotechnology and disease management, are available on AdisOnline (http://adisonline.com).  For more information, visit the company's website at www.wolterskluwerpharma.com.

About Wolters Kluwer Pharma Solutions

Wolters Kluwer Pharma Solutions, Inc. (Bridgewater, NJ) provides clinical and healthcare data and analytics, leading medical publishing services, and market intelligence tools to professionals in the pharmaceutical, biotech, and medical device fields. The company's brands include Adis, Source® and VisionCare Group. The global publisher Adis, provides peer-reviewed journals promoting rational drug therapy and effective patient management, and offers highly respected drug and clinical trials databases. A longstanding provider of market data and healthcare analytics, Source® offers a unique set of comprehensive patient and physician-level prescribing and usage data. VisionCare Group is a publisher of business and specialty publications and producer of conferences and e-media products targeting the vision market. For more information, visit www.wolterskluwerpharma.com.

The company is a wholly owned subsidiary of Wolters Kluwer, U.S., part of Wolters Kluwer, a market-leading global information services company. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance, and healthcare rely on Wolters Kluwer's leading, information-enabled tools and solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.

Wolters Kluwer has 2009 annual revenues of euro 3.4 billion ($4.8 billion), employs approximately 19,300 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices.

Visit our website, YouTube or follow @Wolters_Kluwer on Twitter for more information about our customers, market positions, brands, and organization.

SOURCE Wolters Kluwer Pharma Solutions, Inc.